Acral erythema has been reported in patients receiving sustained dosing (or those who could use prolonged exposure) of the cytotoxic drugs fluorouracil, capecitabine, cytarabine, sorafenib, sunitinib, and pegylated liposomal doxorubicin.
Tingling and/or numbness (aka paresthesias) in the palms and soles are the first symptoms, which then evolve into painful well-demarcated symmetrical swelling and red plaques, followed by peeling and symptom resolution.
Acral erythema, with similar clinical and histological features, can also occur after bone marrow transplant due to dermatologic manifestations of graft vs. host disease.
Symptoms generally resolve 1 to 2 weeks after discontinuing chemotherapy. Results from small clinical studies suggest that corticosteroids may be helpful in relieving symptoms, and that frequent applications of emollients to the hands and feet may help prevent the disorder. The offending anticancer drug may be reintroduced at lower doses once the side effects have abated.
Acral erythema is an adverse drug reaction to chemotherapy that can occur days to months after a patient begins treatment and results in reddening, swelling and desquamation of the skin, often of the palms and soles. The syndrome is also referred to as hand-foot syndrome, palmar-plantar erythrodysesthesia, and Burgdorf’s reaction.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
- Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|